This episode provides an in-depth overview of recent regulatory developments impacting healthcare, finance, and policy sectors within the European Union.

Listeners will learn about the European Medicines Agency’s decisions including the refusal of marketing authorisation for Qezzaqar due to safety concerns, and the withdrawal of applications for Azacitidine Adienne and Dupixent, highlighting ongoing quality and efficacy challenges. Additionally, the European Central Bank’s monetary policy stance is discussed, emphasizing their commitment to managing inflation through a flexible approach.

Further, the podcast examines the introduction of guidelines for veterinary RNA-based therapies, illustrating the EU’s proactive regulatory framework for emerging medical technologies. The episode also touches on state-directed payments, healthcare affordability, tax reduction initiatives, and joint financial regulatory efforts between the EU and the US.

For more information, visit the Carver Agents website.

Articles mentioned:

1. Attorney General Bonta Stands Up for Affordability, Challenges Trump Administration’s Proposal to Cut Medicaid Payments to Healthcare Providers
2. Warnings from other countries - 25.07.2026 - ELITE UNION SAVINGS
3. Le taux de TVA est réduit à 5,5 % pour les pompes à chaleur air/air
4. Concept paper on the quality and safety aspects of RNA interference and RNA antisense oligonucleotide therapies as veterinary medicinal products
5. Human medicines European public assessment report (EPAR): Qezzaqar, catequentinib, Status: Opinion
6. Human medicines European public assessment report (EPAR): Azacitidine Adienne, azacitidine, Status: Application withdrawn
7. Withdrawn application: Dupixent, 24/06/2026
8. Joint Statement on the EU-U.S. Joint Financial Regulatory Forum
9. International Criminal Court Prosecutor Karim Khan dismissed
10. Pressekonferenz am 23. Juli 2026 – Erklärung zur Geldpolitik